TABLE 5.

Effect of delay in initiation of T-705 treatment on an influenza A (H5N1) virus infection in mice

Expt no. and treatmenta	Time of start of therapy (h)	Infected, treated mice
		No. of survivors/total no. tested	MDDb ± SDc	Mean day 11 SaO2 (%) ± SDc
Expt 1
T-705, 300 mg/kg/day	24	10/10***	>21.0***	85.3 ± 5.7***
T-705, 300 mg/kg/day	36	9/9***	>21.0***	84.6 ± 5.9***
T-705, 300 mg/kg/day	48	9/10***	4.0 ± 0.0	87.1 ± 6.2***
T-705, 300 mg/kg/day	60	10/10***	>21.0***	84.6 ± 6.6***
0.4% CMC	24	0/20	7.0 ± 0.5	75.0 ± 0.0
Healthy controls				92.6 ± 3.5
Expt 2
T-705, 300 mg/kg/day	72	9/10***	7.0 ± 0.0	84.1 ± 5.5***
T-705, 300 mg/kg/day	84	10/10***	>21.0***	81.7 ± 3.6**
T-705, 300 mg/kg/day	96	8/9***	7.0 ± 0.0	81.2 ± 3.4**
T-705, 300 mg/kg/day	120	3/10*	7.9 ± 2.6	76.0 ± 1.3
0.4% CMC	72	0/20	7.9 ± 2.7	75.1 ± 0.5
Healthy controls				86.4 ± 3.4

^aEvery 6 h for 5 days.

^bMDD, mean day to death of mice dying prior to day 21.

^c*, P < 0.05 compared to the results for the CMC-treated controls; **, P < 0.01 compared to the results for the CMC-treated controls; ***, P < 0.001 compared to the results for the CMC-treated controls.